XML 14 R5.htm IDEA: XBRL DOCUMENT v3.21.2
Condensed Consolidated Statements of Shareholders' Equity (Unaudited) - USD ($)
$ in Thousands
Common Stock [Member]
Retained Earnings [Member]
Total
Beginning balance, value at Dec. 31, 2019 $ 124,583 $ (93,745) $ 30,838
Beginning balance, shares at Dec. 31, 2019 57,032    
Net Loss (23,623) (23,623)
Stock-based compensation 4,081 4,081
Sale of common shares, including at-the-market transactions $ 18,343 18,343
Sale of common shares, including at-the-market transactions, shares 8,257    
Financing costs paid to issue common shares, including at-the-market transactions $ (58) (58)
Exercise of stock options $ 72 72
Exercise of stock options, shares 33    
Shares issued upon vesting of RSU, net of shares retired to pay employees’ taxes $ (14) (14)
Shares issued upon vesting of RSU, net of shares retired to pay employees’ taxes, shares 13    
Issuance of common stock for Insight Genetics acquisition $ 5,000 5,000
Issuance of common stock for Insight Genetics acquisition, shares 1,916    
Ending balance, value at Sep. 30, 2020 $ 152,007 (117,368) 34,639
Ending balance, shares at Sep. 30, 2020 67,251    
Beginning balance, value at Jun. 30, 2020 $ 150,178 (110,585) 39,593
Beginning balance, shares at Jun. 30, 2020 67,218    
Net Loss (6,783) (6,783)
Stock-based compensation 1,784 1,784
Financing costs paid to issue common shares, including at-the-market transactions (27) (27)
Exercise of stock options $ 72 72
Exercise of stock options, shares 33    
Ending balance, value at Sep. 30, 2020 $ 152,007 (117,368) 34,639
Ending balance, shares at Sep. 30, 2020 67,251    
Beginning balance, value at Dec. 31, 2020 $ 157,160 (123,677) 33,483
Beginning balance, shares at Dec. 31, 2020 69,117    
Net Loss (28,212) (28,212)
Stock-based compensation 5,136 5,136
Sale of common shares, including at-the-market transactions $ 77,987 77,987
Sale of common shares, including at-the-market transactions, shares 19,536    
Financing costs paid to issue common shares, including at-the-market transactions $ (3,065) (3,065)
Exercise of stock options $ 2,573 2,573
Exercise of stock options, shares 894    
Warrants exercised $ 2,631 2,631
Warrants exercised, shares 828    
Shares issued upon vesting of RSU, net of shares retired to pay employees’ taxes $ (239)   (239)
Shares issued upon vesting of RSU, net of shares retired to pay employees’ taxes, shares 153    
Issuance of common stock to Razor Genomics $ 5,756 5,756
Issuance of common stock to Razor Genomics, shares 982    
Issuance of common stock to Chronix Biomedical $ 3,299 3,299
Issuance of common stock to Chronix Biomedical, shares 648    
Ending balance, value at Sep. 30, 2021 $ 251,238 (151,889) 99,349
Ending balance, shares at Sep. 30, 2021 92,158    
Beginning balance, value at Jun. 30, 2021 $ 240,755 (138,089) 102,666
Beginning balance, shares at Jun. 30, 2021 90,316    
Net Loss (13,800) (13,800)
Stock-based compensation 1,849 1,849
Sale of common shares, including at-the-market transactions $ 6,241 6,241
Sale of common shares, including at-the-market transactions, shares 1,109    
Financing costs paid to issue common shares, including at-the-market transactions $ (187) (187)
Exercise of stock options $ 974 974
Exercise of stock options, shares 137    
Warrants exercised $ 1,808 1,808
Warrants exercised, shares 573    
Shares issued upon vesting of RSU, net of shares retired to pay employees’ taxes $ (202) (202)
Shares issued upon vesting of RSU, net of shares retired to pay employees’ taxes, shares 23    
Ending balance, value at Sep. 30, 2021 $ 251,238 $ (151,889) $ 99,349
Ending balance, shares at Sep. 30, 2021 92,158